Company Overview
About Reshape Biotech
Reshape Biotech is a Copenhagen, Denmark-based laboratory automation robotics company — backed by Y Combinator (W21) with $28.2 million in total funding including a $20 million Series A led by Astanor Ventures in April 2024 with participation from YC — providing biotechnology companies, life sciences research organizations, and food technology companies with specialized single-function robots that automate repetitive microbiological laboratory workflows, generating $8.3 million in annual revenue in 2024 with a 55-person team. Reshape's robots have saved customers over 500,000 hours of manual lab work annually, serving the sustainable food technology and alternative protein sector (fermentation-based food production, precision fermentation, cultivated meat) alongside traditional biotech research laboratories that use microbiology workflows at scale.
Business Model & Competitive Advantage
Reshape Biotech's robot design philosophy ('one robot, one task') addresses the ergonomics and accuracy failure modes of manual microbiological workflows: the tedious, repetitive nature of tasks like inoculating hundreds of culture plates, filling growth media into multi-well plates, or analyzing colonies under microscopes creates both human error (accuracy degrading with fatigue on repetitive tasks) and ergonomic injury risk for laboratory workers performing thousands of pipetting motions per shift. Reshape builds dedicated robots optimized specifically for each workflow — the Reshape Plate Filler (automated liquid handling into culture plates), the Reshape Streaker (automated bacterial streaking for colony isolation), and the Reshape Colony Counter (AI-powered image analysis for colony counting and classification) — rather than attempting general-purpose lab automation that trades depth for breadth. The mechatronics engineering (compact robotic hardware designed for standard lab bench footprints) and machine learning image analysis (interpreting microscopy and plate imaging data with expert-level accuracy) combine to create the accuracy and throughput improvements that justify capital investment.
Competitive Landscape 2025–2026
In 2025, Reshape Biotech competes in the laboratory automation, life sciences robotics, and biotech lab equipment market with Hamilton Robotics (Hamilton Company, liquid handling robots), Azenta Life Sciences (NASDAQ: AZTA, integrated biobanking and lab automation), and Opentrons (accessible lab automation robots, $200M raised) for biotech laboratory team workflow automation adoption. The sustainable food technology market (alternative proteins, precision fermentation) has grown rapidly as food companies invest in fermentation-based manufacturing that uses the same microbiology workflows (plating, counting, inoculating) as pharmaceutical biotech — creating a new customer segment for lab automation beyond traditional drug discovery. Astanor Ventures' food system investment focus (Astanor is a leading food and agriculture technology VC) reflects the sustainable food tech application of Reshape's platform. Y Combinator W21 backing connected Reshape with the life sciences and climate tech investor community. The 2025 strategy focuses on growing the alternative protein and precision fermentation customer base, building the automated microbiology workflows for industrial fermentation process development, and expanding the robot-as-a-service subscription model for laboratory teams without capital equipment procurement budgets.
Open Positions
Reddit Discussions
Key Differentiators
Strong Challenger
Reshape Biotech is an established challenger with significant market presence and competitive offerings in Healthcare.
Frequently Asked Questions
Not So Random Others
Yoneda Labs
Yoneda Labs is a San Francisco-based AI company applying foundation models to automate chemical reaction optimization for drug discovery and pharmaceutical process development — providing chemists wit
Decoda Health
Decoda Health is a San Francisco-based AI healthcare administration platform — backed by Y Combinator (S23) with $4.5 million raised from YC, Amino Capital, Bossa Nova Ventures, Cadenza Ventures, Grap
Fortuna Health
Fortuna Health is a New York City-based healthcare technology company — backed by Y Combinator with $22 million in total funding including an $18 million Series A in July 2025 led by Andreessen Horowi
Brisk
Brisk is a functional beverage brand offering ready-to-drink iced tea and juice drinks, jointly owned by PepsiCo and Unilever under the Lipton brand partnership. Launched in the 1990s, Brisk positione
Altria
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and s
AbbVie
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Sp
Compare Reshape Biotech with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Reshape Biotech? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Reshape Biotech Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Reshape Biotech vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →